Evidence-informed guidance for the clinical use of oral semaglutide in obesity management

This review offers practical guidance for using oral semaglutide in obesity management. It reports that oral semaglutide produces weight loss comparable to subcutaneous GLP-1 therapies and improves cardiometabolic risk factors, while stressing strict administration conditions: an empty stomach, no more than 120 mL of water, and a 30-minute wait before food, drink, or other oral medicines.

Narrative review — Review and clinical guidance. Population: Adults with obesity, with additional context for type 2 diabetes and cardiovascular risk reduction. Interventions: oral semaglutide.

The abstract reports no numerical trial results. It states that oral semaglutide demonstrates weight loss comparable to that of subcutaneous GLP-1 therapies, alongside improvements in cardiometabolic risk factors. Practical guidance specifies taking the tablet first thing in the morning on an empty stomach with no more than 120 mL or 4 fl oz of plain water, then waiting 30 minutes before eating, drinking, or taking other oral medications.

Researchers working on semaglutide would use this review to understand the practical administration requirements that can affect absorption and effectiveness of the oral formulation, and to see how oral semaglutide is positioned against subcutaneous GLP-1 therapies in obesity management. It does not establish new efficacy or safety results, and it does not provide dose-response or long-term outcome data.

Key findings

Oral semaglutide demonstrates weight loss comparable to subcutaneous GLP-1 therapies, alongside improvements in cardiometabolic risk factors.
Oral semaglutide tablets should be taken first thing in the morning on an empty stomach with no more than half a glass of plain water (up to 120 mL or 4 fl oz).
After taking oral semaglutide, patients should wait 30 minutes before eating food, drinking additional fluids, or ingesting other oral medications.
Oral semaglutide is approved for obesity management and cardiovascular risk reduction in adults.

Limitations

Guidance is based on selected trial evidence and the authors' clinical insights rather than a systematic review.
No individual patient data or new efficacy results are presented.
The abstract reports no long-term safety or comparative outcome data.
Administration recommendations are presented as practical guidance rather than as findings from a dedicated prospective study.

The record

Journal: Postgraduate medicine 138(6): 654-664
Published: 2026-06-12
PMID: 42286992 — DOI: 10.1080/00325481.2026.2686467
MeSH terms: Humans, Diabetes Mellitus, Type 2, Obesity, Weight Loss, Anti-Obesity Agents, Administration, Oral, Evidence-Based Medicine, Glucagon-Like Peptides, Practice Guidelines as Topic, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide
Funding: Novo Nordisk A/S
Author countries: Canada, USA

Peptide profiles: Semaglutide.

All indexed evidence: Semaglutide trials & papers.